TG Therapeutics Raises 2026 Revenue Forecast to About $1 Billion as BRIUMVI Sales Grow
Key Facts
On November 9, TG Therapeutics raised its 2026 global revenue forecast to about $1 billion, from previous guidance of about $950 million. The company announced the revision alongside its third-quarter results, citing growth in U.S. sales of BRIUMVI. U.S. net product revenue reached $232.6 million for the quarter, an increase of about 52% from the same period a year earlier. That puts the product’s performance at the center of the change in the annual forecast, with the U.S. market accounting for the figures the company reported. The company also raised its estimate for full-year U.S. net revenue from BRIUMVI.
The company set its new guidance range for U.S. BRIUMVI revenue at $915 million to $920 million, up from $890 million to $905 million. The revision is part of an increase in the annual global forecast from about $950 million to about $1 billion. For the quarter, net product revenue was $240.0 million, compared with $159.3 million in the third quarter of 2025. The comparison shows an increase in net product revenue between the periods, while global revenue in the second quarter of 2026 was about $240 million. The company announced in August that it had raised its annual global target to about $950 million, before the latest update.
Revenue growth was accompanied by higher quarterly operating expenses. Research and development expenses were $51.3 million in the third quarter, compared with $40.9 million a year earlier. The company attributed the increase mainly to manufacturing the subcutaneous formulation of BRIUMVI, costs to operate a contract manufacturer and pipeline trials. Selling, general and administrative expenses also rose to $80.7 million from $63.4 million in the comparable period. The company linked the increase in this category mainly to marketing, media and employee costs associated with promoting the treatment. Meanwhile, it kept its target operating expense guidance for 2026 at $450 million to $500 million, excluding noncash compensation.
The company had $556.7 million in cash and cash equivalents and investment securities on September 30, 2026. TG Therapeutics said its liquidity and expected revenue from BRIUMVI were sufficient to fund its business under its current operating plan. In product development, the company is targeting a Phase 3 trial comparing two subcutaneous injection regimens with the approved intravenous regimen. The design includes one regimen dosed every 8 weeks and another every 12 weeks, alongside the intravenous treatment arm. The company expects to announce topline data near the end of 2026 or during the first quarter of 2027.